Type 2 diabetes mellitus--current therapies and the emergence of surgical options (Q37837496)

24 August 2017

1 reference

title

Type 2 diabetes mellitus--current therapies and the emergence of surgical options (English)

1 reference

24 August 2017

0 references

Harold E Lebovitz

1

1 reference

24 August 2017

8 February 2011

1 reference

24 August 2017

12

1 reference

Nature Reviews Endocrinology

inferred from page(s)

published in

1 reference

24 August 2017

7

1 reference

24 August 2017

7

1 reference

24 August 2017

408-419

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2011.10

24 August 2017

0 references

cites work

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Bariatric surgery: risks and rewards

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/21301486

12 December 2020

inferred from PubMed ID database lookup

beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Combination therapies with insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Metformin: new understandings, new uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Adjunct therapy for type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Treatment of insulin resistance in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Three-year efficacy of complex insulin regimens in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Is glycemic control improving in U.S. adults?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Improvements in risk factor control among persons with diabetes in the United States: evidence and implications for remaining life expectancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

The role of genetics in susceptibility to diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Correlates of insulin injection omission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Primary care physician beliefs about insulin initiation in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Intensive versus conventional glucose control in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Use of thiazolidinediones and fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Fat and beyond: the diverse biology of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Revisiting the rosiglitazone story--lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Regulatory action on rosiglitazone by the U.S. Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Long-term mortality after gastric bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Narrative review: effect of bariatric surgery on type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Bariatric surgery: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Trends in mortality in bariatric surgery: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Long-term follow-up of the metabolic profiles in obese patients with type 2 diabetes mellitus after Roux-en-Y gastric bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Effect of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI>35 and <35 kg/m2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

The effect of bariatric surgery on gut hormones that alter appetite

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Relationship between surgeon volume and adverse outcomes after RYGB in Longitudinal Assessment of Bariatric Surgery (LABS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Medical follow up after bariatric surgery: nutritional and drug issues. General recommendations for the prevention and treatment of nutritional deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Fluid retention with thiazolidinediones: does the mechanism influence the outcome?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Comparison of peripheral and portal (via the umbilical vein) routes of insulin infusion in IDDM patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Impact of gastric bypass operation on survival: a population-based analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

The gut hormone response following Roux-en-Y gastric bypass: cross-sectional and prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

Nutritional deficiencies after Roux-en-Y gastric bypass for morbid obesity often cannot be prevented by standard multivitamin supplementation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.10

The kinetics of insulin in man. II. Role of the liver

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21301486

12 December 2020

inferred from PubMed ID database lookup

Effect of Laparoscopic Roux-En Y Gastric Bypass on Type 2 Diabetes Mellitus

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21301486

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/NRENDO.2011.10

1 reference

24 August 2017

1 reference

PubMed ID

21301486